CVI Pharmaceuticals has presented preclinical data on their thyroid hormone receptor beta (THRB) selective agonist CVI-2742 for the potential treatment of NASH. Selective activation of the THRB contributes to ameliorating the symptoms of nonalcoholic steatohepatitis (NASH), such as liver inflammation and fibrosis, hepatocyte ballooning and liver steatosis.

Researchers from Ipsen Ltd. and affiliated organizations presented the discovery and preclinical characterization of a novel NTCP inhibitor, A-7387, being developed for the treatment of HBV and HDV infections.

Omega Therapeutics Inc. has presented preclinical data on hepatocyte nuclear factor 4-alpha (HNF4A) modulation in fibrotic liver disease models to enhance its key role and suggest it as a potent therapeutic target.

Genfit SA has highlighted its new focus and development strategy in acute-on-chronic liver failure (ACLF). The company's pipeline targets key pathophysiological pathways of ACLF, with priority given to systemic inflammation, cell death and microbiota.

Trex Bio Inc. has announced its selection of a new development candidate, TRB-061, designed to selectively agonize TNF receptor 2 (TNFR2), a mechanism with potential across a broad range of autoimmune indications.

Researchers from the University of Michigan have filed for patent protection of methods and systems to identify actual esophageal tissue changes and/or damage during cardiac ablation procedures.

Sosei Group Corp. and Kallyope Inc. have announced the successful identification, validation and nomination of a first G protein-coupled receptor (GPCR) target to enter a therapeutic discovery program for gastrointestinal (GI) diseases. The nominated target will advance into a structure-based drug discovery program.